EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Osteoporosis After Menopause and After Drug Therapy: The Molecular Mechanism of Bone Loss and Its Treatment

Kelly I-Rong Lee, Jie-Hong Chen, Kuo-Hu Chen iD

International Journal of Molecular Sciences · 08.01.2026 · 27 (2) · 641

DOI: 10.3390/ijms27020641 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.01.2026. Verfasst von Kelly I-Rong Lee und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, College of Medicine, MacKay Medical University, New Taipei City 25245, Taiwan. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Osteoporosis, Postmenopausal, Osteoporosis. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taipei Tzu Chi Hospital, Taipei Tzu-Chi Hospital, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Osteoporosis is a prevalent skeletal disorder characterized by reduced bone mass and microarchitectural deterioration, leading to increased fracture risk, particularly in aging populations. Postmenopausal osteoporosis (PMOP) remains the most common primary form and results from abrupt estrogen deficiency after menopause, which disrupts bone remodeling by accelerating the receptor activator of nuclear factor-κB ligand (RANKL)-mediated osteoclastogenesis, suppressing Wnt/β-catenin signaling, and promoting inflammatory cytokine production. In contrast, drug-induced osteoporosis (DIOP) encompasses a heterogeneous group of secondary bone disorders arising from pharmacologic exposures. Glucocorticoids suppress osteoblastogenesis, enhance osteoclast activity, and increase reactive oxygen species; long-term bisphosphonate therapy may oversuppress bone turnover, resulting in microdamage accumulation; denosumab withdrawal triggers a unique rebound surge in RANKL activity, often leading to rapid bone loss and multiple vertebral fractures. Medications including aromatase inhibitors, SSRIs, proton pump inhibitors, heparin, and antiepileptic drugs impair bone quality through diverse mechanisms. Standard antiresorptive agents remain first-line therapies, while anabolic agents such as teriparatide, abaloparatide, and romosozumab provide enhanced benefits in high-risk or drug-suppressed bone states. Transitional bisphosphonate therapy is essential when discontinuing denosumab, and individualized treatment plans—including drug holidays, lifestyle interventions, and monitoring vulnerable patients—are critical for optimizing outcomes. Emerging approaches such as small interfering RNA (siRNA)-based therapeutics, anti-sclerostin agents, digital monitoring technologies, and regenerative strategies show promise for future precision medicine management. Understanding the distinct and overlapping molecular mechanisms of osteoporosis is essential for improving fracture prevention and long-term skeletal health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Density Conservation AgentsOsteoporosis, PostmenopausalOsteoporosisHumansFemaleDenosumabAnimalsBone RemodelingDiphosphonatesRANK Ligand

Stichwörter der Autor:innen

drug induced osteoporosisosteoporosispostmenopausal osteoporosistreatment of osteoporosis

Substanzen

Bone Density Conservation AgentsDenosumabDiphosphonatesRANK Ligand

Autor:innen und Institutionen

  • School of Medicine, College of Medicine, MacKay Medical University, New Taipei City 25245, Taiwan.
  • Department of Obstetrics and Gynecology, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, New Taipei City 23142, Taiwan.
  • School of Medicine, Tzu-Chi University, Hualien 97004, Taiwan.

ORCID-Profile: Kuo-Hu Chen

Förderung

  • Taipei Tzu Chi Hospital
  • Taipei Tzu-Chi Hospital, Taiwan

Zitieren

APA

Lee, K. I., Chen, J. H., & Chen, K. H. (2026). Osteoporosis After Menopause and After Drug Therapy: The Molecular Mechanism of Bone Loss and Its Treatment. International Journal of Molecular Sciences, 27(2), 641. https://doi.org/10.3390/ijms27020641

Vancouver

Lee KI, Chen JH, Chen KH. Osteoporosis After Menopause and After Drug Therapy: The Molecular Mechanism of Bone Loss and Its Treatment. International Journal of Molecular Sciences. 2026;27(2):641. doi:10.3390/ijms27020641

BibTeX
@article{Lee2026,
  author = {Lee, Kelly I-Rong and Chen, Jie-Hong and Chen, Kuo-Hu},
  title = {Osteoporosis After Menopause and After Drug Therapy: The Molecular Mechanism of Bone Loss and Its Treatment},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {2},
  pages = {641},
  doi = {10.3390/ijms27020641}
}
Kostenlos starten →